Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported revenues of NOK 138.9 million in the third quarter of 2025, a 12.9% increase from the same period in 2024.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024, and Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million, a 12.9% increase from Q3 2024
- Gross margin: 37.5%, compared to 37.1% in Q3 2024
- Adjusted EBITDA: NOK 11.3 million, up from NOK 8.6 million in 2024
The overall revenues performance was driven by increases in all three business areas.
Author's summary: Navamedic ASA reports double-digit growth in Q3 2025.
More News
- The price of going cashless
- Britain’s failing state is handing Farage win after win
- Why Impact Investing Might Collapse and How to Stop It (SSIR)
- Lahti, Finland chooses most beautiful building as city celebrates 120th anniversary - thisisFINLAND
- Tackling youth vaping: Current regulations fall short and new tech offers effective solutions
- Mike Brown is quickly reaching a crushing realization Knicks fans already knew
- The Sundarbans: Our shield against climate change
- Obituaries – Week of Oct. 27, 2025 - The Observer
- The Coming Dementia Crisis—and the Cost of Doing Nothing
- MLB: Last time each team won the World Series